Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × 90Y-octreotide, DOTA-Tyr(3)- × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Completed 3 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 149 Bevacizumab 138 Docetaxel 135 Carboplatin 135 pembrolizumab 130 Cisplatin 127 Radiotherapy 125 Gemcitabine 123 Paclitaxel 119 Capecitabine 108 Rituximab 105 Fluorouracil 97 Oxaliplatin 92 Nivolumab 83 Irinotecan 80 Leucovorin 77 Doxorubicin 76 Dexamethasone 73 Pemetrexed 70 fludarabine 66 fludarabine phosphate 63 Etoposide 63 Bortezomib 60 Erlotinib Hydrochloride 59 Methotrexate 54 Cetuximab 54 Cytarabine 52 Trastuzumab 51 Sorafenib 46 Prednisone 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488512 2018-03-19

itTRIOlym

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡